Summit Therapeutics Inc. (SMMT) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Summit Therapeutics (SMMT) by buying shares or fractional shares at any major broker, through a biotech ETF that holds it, or as one holding in a thematic basket. Summit is a clinical-stage biopharmaceutical company whose value is tied almost entirely to ivonescimab, a PD-1/VEGF bispecific antibody in late-stage development for non-small cell lung cancer. As a pre-revenue biotech, it is a high-risk, event-driven stock whose price swings on trial readouts and regulatory decisions, not earnings. In mid-November 2026 the FDA declined to approve ivonescimab in its first US application, citing the lack of a clear survival benefit, and said a new trial is needed. As of November 20, 2026 the shares closed at about $10.02, a 52-week low, down about 43% year to date (a market value near $8.0 billion), well below the $18.36 per share AstraZeneca paid in October.

SMMT stock price

As of 2026-11-20, Summit Therapeutics Inc. (SMMT) last closed at $9.95, down 38.5% over the past year. Over the past 52 weeks it has traded between $9.95 and $26.38.

SMMT last close
$9.95
1 day
-5.87%
1 month
-37.14%
1 year
-38.54%
52-week range
$9.95 to $26.38
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Summit Therapeutics Inc.'s investor relations page. Walnut is informational, not investment advice.

SMMT key stats

At $9.95 on November 20, 2026, Summit Therapeutics Inc. (SMMT) has a market cap of $8.0B.

Market cap
$8.0B
Price to book
14.1

Market cap, P/E and yield are measured at the $9.95 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Summit Therapeutics Inc. (SMMT)?

The last two weeks for Summit Therapeutics Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • SMMT closed at $9.95 on November 20, 2026, down 29.7% over the past five trading days (from $14.15).
  • On November 18, 2026, Summit Therapeutics Inc. filed an 8-K with the SEC reporting other events (Item 8.01). Read the 8-K on sec.gov
  • On November 16, 2026, Summit Therapeutics Inc. filed an 8-K with the SEC reporting other events (Item 8.01). Read the 8-K on sec.gov
  • On November 18, 2026, Bernstein lowered its target to $8.30 from $11.90 (Underperform).
  • On November 16, 2026, Citigroup lowered its target to $42.00 from $43.00 (Buy).
  • On November 16, 2026, Barclays lowered its target to $18.00 from $20.00 (Equal-Weight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Summit Therapeutics Inc. (SMMT) do?

Summit Therapeutics is a clinical-stage biopharmaceutical company focused almost entirely on ivonescimab, a first-in-class tetravalent bispecific antibody that targets both PD-1 and VEGF simultaneously. Summit in-licensed ivonescimab from China's Akeso in January 2023 and holds rights to develop and commercialize it across North America, South America, Europe, the Middle East, Africa, and Japan, while Akeso keeps China and certain other regions. The lead opportunity is non-small cell lung cancer (NSCLC), where Phase III data in China have shown ivonescimab extending progression-free survival versus Merck's Keytruda (pembrolizumab), plus additional programs in colorectal and other cancers. The company generates no meaningful product revenue yet and funds operations from its cash balance while running large global trials.

The investment picture is that of a high-risk, high-reward binary biotech, and the first big binary went against it. The FDA had accepted a Biologics License Application in January 2026 for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy, with a November 14, 2026 decision date. In a complete response letter that the agency published on November 17, the FDA declined to approve, questioning the size of the effect on tumor progression and its relevance to US patients, and concluding that the modest benefits did not outweigh the added safety risks; Summit said the decision was driven by the lack of a clear survival benefit, and the FDA said a new trial would be needed. Leerink Partners wrote that a resubmission on its own is unlikely to change the outcome, and Bernstein downgraded the stock to Underperform with an $8.30 target. Summit has scheduled a corporate update call for November 30, 2026, and on November 18 it started HARMONi-10, a new Phase III in unresectable Stage III NSCLC.

Funding is not the immediate problem. On October 5, 2026 AstraZeneca completed a $2 billion equity investment, buying convertible preferred stock equal to about 109 million common shares at an implied $18.36 per share, and the companies agreed to study ivonescimab with AstraZeneca and Daiichi Sankyo's antibody drug conjugate Datroway. That capital came on top of about $630 million of cash Summit held at September 30, 2026, against a third-quarter net loss of about $155 million ($0.19 per share, versus a $0.21 consensus loss). The stock has fallen hard: it closed at about $10.02 on November 20, 2026, down about 35% in a month, 43% year to date and 39% over one year. Positive global Phase III data could still open a large commercial market against a Keytruda franchise worth tens of billions, but the US path is now longer and less certain. This is a speculative, event-driven holding, not an income or earnings stock.

What's driving Summit Therapeutics Inc. (SMMT)?

1. Ivonescimab FDA review and first approval.

The FDA reviewed Summit's BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after TKI therapy, with a target decision date of November 14, 2026, and issued a complete response letter instead of an approval. The agency cited a modest effect on tumor progression, questions about relevance to US patients, safety risks that the benefit did not outweigh, and, per Summit, the lack of a clear survival benefit, and it said a new trial is needed. A first US approval now depends on new data, and Summit's November 30, 2026 update call is the next point where the company may lay out its regulatory plan.

2. Head-to-head data versus Keytruda.

Phase III studies have shown ivonescimab roughly doubling progression-free survival versus Keytruda (pembrolizumab) monotherapy in PD-L1-positive NSCLC in China, and the HARMONi-6 study reported a statistically significant overall survival benefit in squamous NSCLC. After the FDA's focus on survival and US relevance, global confirmatory trials such as HARMONi-3 (versus pembrolizumab plus chemotherapy, results expected 2027) and HARMONi-7 matter even more. If they replicate that advantage with survival data, ivonescimab could still challenge the largest oncology franchise in the world. These readouts are now the central swing factors for the stock.

3. Pipeline breadth and partnerships.

Summit is expanding ivonescimab beyond first-line NSCLC into colorectal cancer (the AK112-206 Phase II with data at ASCO 2026), unresectable Stage III NSCLC (the HARMONi-10 Phase III, started November 18, 2026) and other tumor types, and is building a set of antibody drug conjugate combinations: a clinical collaboration with GSK on its B7-H3 ADC, and, in October 2026, collaborations with AstraZeneca and Daiichi Sankyo on Datroway and on sonesitatug vedotin. More than 5,000 patients have been treated with ivonescimab in global clinical studies, plus over 100,000 including commercial use in China through Akeso, and five Phase III ivonescimab trials have read out positive. Broader indications and combinations could widen the eventual market opportunity.

4. AstraZeneca's $2 billion and the cash runway.

Summit held about $630 million in cash at September 30, 2026, after net losses of about $139 million in the first quarter, $162 million in the second and $155 million in the third. On October 5, 2026 AstraZeneca completed a $2 billion equity investment through convertible preferred stock at an implied $18.36 per common share, about 109 million common-share equivalents. The money is earmarked to support ADC combination work and gives Summit a far larger cushion to run the additional trials the FDA now wants. The trade-off is dilution of roughly 14% relative to the share count of about 776 million, and a large strategic holder whose own pipeline overlaps with Summit's and who paid well above today's price.

What are the risks to Summit Therapeutics Inc. (SMMT)?

Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab, and the November 2026 FDA rejection shows that risk is real: the agency found the benefit modest relative to safety risks and asked for a new trial, which delays any US launch by years if the next data are positive and could end the US program if they are not. Further failed trials, negative regulatory decisions in other regions, or unexpected safety findings could sharply reduce the company's value again. The competitive field is intensifying, with Pfizer/3SBio and Bristol Myers Squibb/BioNTech (pumitamig) also developing PD-1/PD-L1 by VEGF bispecifics, and Merck's Keytruda is the entrenched standard of care; a longer US timeline gives rivals room to catch up. The company depends on its license from Akeso and on manufacturing and clinical execution across many regions. AstraZeneca's $2 billion investment eases funding pressure, but it was itself dilutive, and with net losses running about $140-165 million a quarter and no product sales, further raises remain possible over a longer development path. The stock is highly volatile and prone to large single-day moves around catalysts; it fell about 35% in the month to November 20, 2026.

What is the Summit Therapeutics Inc. (SMMT) forecast?

13 analysts publish price targets on SMMT, averaging $28.81 as of November 2026, or +189.5% against the $9.95 share price on November 20, 2026. The published targets run from $8.23 to $42.60, a wide spread, and the ratings split 11 buy, 5 hold, 1 sell. Over the last six months there have been 5 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SMMT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is SMMT a buy or a sell?

We give no verdict on Summit Therapeutics Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Ivonescimab FDA review and first approval. The FDA reviewed Summit's BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after TKI therapy, with a target decision date of November 14, 2026, and issued a complete response letter instead of an approval. The most optimistic published target, $42.60, assumes this works close to its best case.

The case against. Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab, and the November 2026 FDA rejection shows that risk is real: the agency found the benefit modest relative to safety risks and asked for a new trial, which delays any US launch by years if the next data are positive and could end the US program if they are not. The most pessimistic target, $8.23, is roughly what SMMT is worth if this bites instead.

Read the full bull and bear case on SMMT, including what would have to change to break either one. Walnut is not an investment adviser.

Has Summit Therapeutics Inc. (SMMT) split its stock?

No. Summit Therapeutics Inc. (SMMT) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Summit Therapeutics Inc. (SMMT) valued?

Market cap, P/E and dividend yield at today's price are in the SMMT key stats above. The business figures below come from Summit Therapeutics Inc.'s reported results as of November 2026 and change when it next reports.

  • Product revenue (TTM): ~$0 (pre-commercial)
  • Net loss (TTM): ~-$833 million; Q3 2026 net loss ~-$155 million ($0.19 per share vs ~$0.21 est.)
  • Cash (September 30, 2026): ~$630 million, before AstraZeneca's $2 billion (closed Oct 5, 2026)
  • AstraZeneca investment: $2 billion at an implied $18.36 per share (~109 million common equivalents)
  • Lead-drug FDA decision: Complete response letter (rejection), November 2026; FDA asked for a new trial

As of November 2026: As a clinical-stage biotech with no meaningful product sales, Summit cannot be valued on earnings or a P/E ratio; its roughly $8.0 billion market value (November 20, 2026) reflects expectations for ivonescimab outside the now-delayed US filing. AstraZeneca's implied $18.36 a share is about 83% above the November 20 close, while Bernstein's new $8.30 target sits below it, and the 13-analyst mean target near $29 largely predates the rejection. Figures are approximate; the November 30 corporate update is the next scheduled event.

Who competes with Summit Therapeutics Inc. (SMMT)?

Standard-of-care checkpoint inhibitors

Merck's Keytruda (pembrolizumab) is the dominant first-line PD-1 immunotherapy in NSCLC and the incumbent ivonescimab is being tested against; Bristol Myers Squibb's Opdivo and Roche's Tecentriq are other established checkpoint inhibitors. These are approved, revenue-generating franchises that ivonescimab would need to displace to reach its potential.

Rival PD-(L)1 by VEGF bispecifics

Pfizer (with 3SBio) and Bristol Myers Squibb with BioNTech (pumitamig) are developing competing PD-(L)1 by VEGF bispecific antibodies aimed at the same next-generation immunotherapy niche. Whichever program shows the best efficacy, safety, and timing could capture the market; Summit was seen as the leader in this class, and the FDA rejection gives rivals a chance to close the gap in the US.

Large-cap oncology developers

Big pharmaceutical and biotech companies such as Merck, Roche/Genentech, AstraZeneca, and Amgen have deep oncology pipelines, cash, and commercial infrastructure. They can out-resource a single-asset biotech like Summit and are pursuing their own lung-cancer and antibody drug conjugate programs that compete for the same patients.

What stocks are similar to Summit Therapeutics Inc. (SMMT)?

Other names that sit close to SMMT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Summit Therapeutics Inc. (SMMT)

There are three common ways to get SMMT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SMMT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SMMT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Summit Therapeutics Inc. (SMMT)

Summit Therapeutics is a clinical-stage biotech that trades as a bet on one drug, ivonescimab, so its outcome hinges on trial data and FDA decisions, not current revenue. It behaves like a binary, catalyst-driven stock: large moves around readouts and approvals, no earnings to anchor valuation, and real risk of failure alongside significant upside if the drug succeeds. The November 2026 FDA rejection pushed the first US approval out by at least one new trial, so AstraZeneca's $2 billion and the 2027 Phase III readouts (HARMONi-3, HARMONi-7) now carry the case.

More on Summit Therapeutics Inc. (SMMT)

Whether SMMT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SMMT a buy or a sell?, and where the stock could go from here in the SMMT stock forecast.

For income investors, whether SMMT pays a dividend and how the payout looks is covered in does SMMT pay a dividend? And to weigh SMMT against a peer, read the full side-by-side comparisons: SMMT vs PD and SMMT vs BMY.

Wondering how SMMT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Summit Therapeutics Inc.

Ask Walnut's AI anything about SMMT and see how it fits what you own.

FAQ

What does Summit Therapeutics do?

+

Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a bispecific antibody that blocks both PD-1 and VEGF. Its main focus is treating non-small cell lung cancer, with additional programs in colorectal and other cancers. It does not yet sell an approved product, and its first US application was rejected in November 2026.

What is ivonescimab?

+

Ivonescimab is a first-in-class tetravalent bispecific antibody that targets PD-1 and VEGF at the same time. Summit licensed it from China-based Akeso in 2023 and is developing it for lung and other cancers. In trials in China it has extended progression-free survival versus Merck's Keytruda in some NSCLC settings, but the FDA concluded in November 2026 that the data in Summit's first application did not show a clear enough benefit.

Is Summit Therapeutics profitable?

+

No. Summit is a pre-revenue clinical-stage biotech with no meaningful product sales, so it runs net losses and burns cash funding its trials. Its net loss was about $139 million in the first quarter of 2026, about $162 million in the second and about $155 million in the third, or roughly $833 million over the trailing twelve months. Profitability would depend on approving and commercializing ivonescimab, which the November 2026 FDA decision pushed further out.

When is the FDA decision on ivonescimab?

+

The decision has been made. The FDA's target date for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy was November 14, 2026, and the agency issued a complete response letter declining approval, which it published on November 17. It questioned the size of the benefit and its relevance to US patients, judged the modest benefit not to outweigh the added safety risks, and said a new trial is needed. Summit said the main issue was the lack of a clear survival benefit.

How much cash does Summit have?

+

Summit reported about $630 million in cash as of September 30, 2026. On October 5, 2026 AstraZeneca completed a $2 billion equity investment, buying convertible preferred stock at an implied $18.36 per common share, which substantially increases the cash available for Phase III trials. Because Summit is pre-revenue, losing roughly $140-165 million a quarter, and now needs an additional trial for US approval, it may still need more capital over time.

Who are Summit Therapeutics' competitors?

+

Ivonescimab competes against established checkpoint inhibitors led by Merck's Keytruda, plus rival PD-(L)1 by VEGF bispecifics from Pfizer/3SBio and Bristol Myers Squibb/BioNTech. Large oncology developers like Roche, AstraZeneca, and Amgen also compete for the same lung-cancer patients.

Why is SMMT stock so volatile?

+

Because Summit is a single-asset, pre-revenue biotech, its value rests on expectations for ivonescimab, not earnings. Trial readouts, FDA decisions, and competitor data can cause large single-day price moves in either direction, which makes the stock speculative and event-driven. The November 2026 FDA rejection is an example: the shares fell about 35% over the month to November 20 and hit a 52-week low of about $10.02.

How can I invest in Summit Therapeutics?

+

SMMT trades on the Nasdaq, so you can buy shares or fractional shares through any major brokerage, hold it via a biotech or healthcare ETF, or include it as one position in a thematic basket. Walnut is not an investment adviser, and this is a high-risk holding to size carefully within a diversified portfolio.

What is the AstraZeneca deal with Summit Therapeutics?

+

On October 5, 2026 AstraZeneca completed a $2 billion equity investment in Summit, purchasing about 108,955 shares of preferred stock convertible at 1,000 common shares each, for an implied price of $18.36 per common share. Alongside it, the companies agreed to study ivonescimab in combination with antibody drug conjugates, including AstraZeneca and Daiichi Sankyo's Datroway and sonesitatug vedotin. The deal does not transfer ivonescimab rights. At the November 20, 2026 close of about $10.02, the shares trade well below AstraZeneca's entry price.

How did Summit Therapeutics do in its latest quarter?

+

For the quarter ended September 30, 2026, Summit reported no product revenue and a net loss of about $155 million, or $0.19 per share, slightly narrower than the roughly $0.21 consensus loss. Cash was about $630 million at quarter end, before the $2 billion AstraZeneca investment closed in October. Weeks later the FDA rejected the first ivonescimab application, and Summit will host a corporate update call on November 30, 2026.

How has SMMT stock performed in 2026?

+

Poorly. SMMT closed around $10.02 on November 20, 2026, its 52-week low, down about 43% year to date, about 39% over one year, about 25% over three months and about 35% in the past month, after the FDA declined to approve ivonescimab. Its 52-week high was about $29.23. Bernstein downgraded the stock to Underperform with an $8.30 target on November 18. This is not investment advice.

Why did the FDA reject ivonescimab, and what happens next?

+

In its November 2026 complete response letter the FDA questioned the magnitude of ivonescimab's effect on tumor progression and how relevant the results were to US patients, and said the modest benefits did not outweigh its added safety risks; Summit said the decision turned on the lack of a clear survival benefit. The FDA said a new trial would be needed, and Leerink Partners wrote that a resubmission alone is unlikely to change the outcome. Global Phase III readouts expected in 2027, including HARMONi-3 against Keytruda plus chemotherapy, are the next major data, and Summit's November 30 update call may add detail.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Summit Therapeutics Inc.'s investor relations page or your broker before making investment decisions.